AU
UK
CA
US
IND
NZ
Last update at 2026-06-05T20:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
High Growth Tech Stocks To Watch In The US Market
Wed 07 May 25, 11:38 AMTop Growth Companies With High Insider Ownership May 2025
Mon 05 May 25, 05:35 PMDiscovering Opportunities: 3 Penny Stocks With Market Caps Over $500M
Mon 14 Apr 25, 06:05 PMInsider-Favored Growth Companies Including Organogenesis Holdings And Two More
Fri 04 Apr 25, 05:05 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 20.28M | 63.79M | 18.48M | -40.30400M | -64.74700M |
| Minority interest | - | - | - | 0.00000M | 0.00000M |
| Net income | 15.53M | 94.90M | 17.95M | -40.45400M | -64.83100M |
| Selling general administrative | 283.81M | 250.20M | 203.48M | 199.69M | 161.96M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 345.87M | 353.86M | 250.98M | 185.03M | 124.64M |
| Reconciled depreciation | 18.03M | 16.68M | 7.47M | 9.43M | 6.98M |
| Ebit | 22.30M | 72.92M | 27.41M | -29.45900M | -47.83600M |
| Ebitda | 40.32M | 89.58M | 34.98M | -20.01500M | -40.85800M |
| Depreciation and amortization | 18.02M | 16.66M | 7.57M | 9.44M | 6.98M |
| Non operating income net other | -0.01300M | -1.89600M | 2.34M | - | - |
| Operating income | 22.30M | 72.92M | 27.41M | -29.45900M | -51.55600M |
| Other operating expenses | 428.59M | 395.14M | 310.88M | 290.44M | 241.51M |
| Interest expense | 2.01M | 7.24M | 11.28M | 9.00M | 10.85M |
| Tax provision | 4.75M | -31.11600M | 0.53M | 0.15M | 0.08M |
| Interest income | - | - | - | 9.00M | 0.06M |
| Net interest income | -2.00900M | -7.23600M | -11.27900M | -8.99600M | -10.78900M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 4.75M | -31.11600M | 0.53M | 0.15M | 0.08M |
| Total revenue | 450.89M | 468.06M | 338.30M | 260.98M | 193.45M |
| Total operating expenses | 323.57M | 280.94M | 223.56M | 214.49M | 172.70M |
| Cost of revenue | 105.02M | 114.20M | 87.32M | 75.95M | 68.81M |
| Total other income expense net | -2.02200M | -9.13200M | -8.93600M | -10.84500M | -5.89600M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 15.53M | 94.90M | 17.95M | -40.45400M | -64.83100M |
| Net income applicable to common shares | 15.53M | 94.90M | 17.95M | -41.09900M | -64.83100M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 460.02M | 449.36M | 443.26M | 294.49M | 220.69M |
| Intangible assets | 15.87M | 20.79M | 25.67M | 30.62M | 20.80M |
| Earning assets | - | - | - | - | - |
| Other current assets | 10.45M | 5.09M | 4.97M | 4.93M | 2.95M |
| Total liab | 181.36M | 183.69M | 201.22M | 148.41M | 165.10M |
| Total stockholder equity | 278.66M | 265.67M | 242.03M | 146.08M | 55.58M |
| Deferred long term liab | - | - | 1.22M | 0.37M | 0.09M |
| Other current liab | 30.07M | 26.45M | 2.30M | 2.06M | 5.81M |
| Common stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.01000M |
| Capital stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.01000M |
| Retained earnings | -40.97100M | -45.30100M | -60.13300M | -153.05800M | -171.00700M |
| Other liab | - | 1.12M | 1.56M | 15.71M | 7.66M |
| Good will | 28.77M | 28.77M | 28.77M | 28.77M | 25.54M |
| Other assets | 0.00000M | 31.53M | 33.53M | 0.69M | 1.57M |
| Cash | 104.34M | 102.48M | 113.93M | 84.39M | 60.17M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 80.51M | 75.02M | 82.00M | 68.22M | 59.89M |
| Current deferred revenue | - | - | 35.72M | 22.49M | 22.64M |
| Net debt | 15.01M | 21.31M | 18.37M | 0.38M | 40.43M |
| Short term debt | 19.71M | 16.25M | 14.64M | 20.29M | 3.06M |
| Short long term debt | 5.49M | 4.54M | 2.66M | 16.67M | - |
| Short long term debt total | 119.35M | 123.79M | 132.30M | 84.77M | 100.61M |
| Other stockholder equity | 319.62M | 310.96M | 302.15M | 299.13M | 226.58M |
| Property plant equipment | - | 102.46M | 79.16M | 60.07M | 47.18M |
| Total current assets | 225.04M | 222.61M | 226.98M | 174.34M | 125.60M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | 216.11M | 187.59M | 86.69M | 9.25M |
| Short term investments | - | - | - | - | - |
| Net receivables | 82.00M | 89.45M | 82.46M | 56.80M | 39.36M |
| Long term debt | 60.74M | 66.23M | 70.77M | 53.04M | 83.12M |
| Inventory | 28.25M | 24.78M | 25.02M | 27.80M | 22.92M |
| Accounts payable | 30.72M | 32.33M | 29.34M | 23.38M | 28.39M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 0.00000M | - | - | - | -65.81200M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 0.01M | 0.01M | 0.01M | 0.01000M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | -45.30100M | -60.13300M | -153.05800M | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 5.99M | 1.52M | 1.54M | 0.67M | 0.88M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 234.98M | 226.75M | 216.28M | 120.15M | 95.09M |
| Capital lease obligations | 53.12M | 53.02M | 58.88M | 15.06M | 17.49M |
| Long term debt total | - | 66.23M | 70.77M | 64.49M | 97.55M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -33.89800M | -31.22000M | -24.83300M | -6.23400M | -1.85600M |
| Change to liabilities | -8.51800M | 6.44M | -0.63500M | 4.70M | -0.06000M |
| Total cashflows from investing activities | -33.89800M | -31.22000M | -24.83300M | -6.23400M | -1.85600M |
| Net borrowings | -2.81300M | 2.24M | -15.91100M | 38.15M | 1.07M |
| Total cash from financing activities | -2.19900M | -1.03600M | 42.47M | 78.73M | 81.64M |
| Change to operating activities | -19.16200M | -3.60100M | -0.00400M | 1.39M | -7.98500M |
| Net income | 15.53M | 94.90M | 17.95M | -40.45400M | -64.83100M |
| Change in cash | -11.23800M | 29.72M | 24.44M | 38.97M | 19.05M |
| Begin period cash flow | 114.53M | 84.81M | 60.37M | 21.41M | 2.36M |
| End period cash flow | 103.29M | 114.53M | 84.81M | 60.37M | 21.41M |
| Total cash from operating activities | 24.86M | 61.98M | 6.80M | -33.52800M | -60.73900M |
| Issuance of capital stock | 0.00000M | 0.00000M | 64.73M | 50.34M | 92.00M |
| Depreciation | 18.03M | 16.68M | 7.47M | 9.43M | 6.98M |
| Other cashflows from investing activities | - | - | 2.13M | 2.13M | 2.13M |
| Dividends paid | - | - | - | -57.89700M | - |
| Change to inventory | -9.41000M | -9.30200M | -6.70000M | -11.06300M | -5.00000M |
| Change to account receivables | -8.77000M | -30.23200M | -18.82500M | -4.69100M | -7.11000M |
| Sale purchase of stock | 2.07M | 2.20M | 61.90M | -6.76200M | 0.12M |
| Other cashflows from financing activities | -1.25600M | 64.15M | 3.65M | 111.90M | 12.33M |
| Change to netincome | 15.23M | -25.46200M | 7.55M | 7.16M | 10.40M |
| Capital expenditures | 33.90M | 31.22M | 21.14M | 6.23M | 1.86M |
| Change receivables | -15.77600M | -34.81000M | -20.34100M | - | - |
| Cash flows other operating | 17.07M | 19.48M | 3.24M | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | -11.23800M | 29.72M | 24.44M | - | - |
| Change in working capital | -34.08200M | -39.28800M | -26.16400M | -9.66700M | -22.40100M |
| Stock based compensation | 6.55M | 3.86M | 1.66M | 0.94M | 1.07M |
| Other non cash items | 16.85M | 17.80M | 5.78M | 6.12M | 18.25M |
| Free cash flow | -9.03900M | 30.76M | -14.34400M | -39.76200M | -62.59600M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ORGO Organogenesis Holdings Inc |
-0.06 2.42% | 2.42 | 66.75 | 12.32 | 0.88 | 1.37 | 0.92 | 11.05 |
| ZTS Zoetis Inc |
-0.08 0.10% | 79.44 | 40.18 | 30.96 | 10.67 | 17.60 | 11.27 | 26.18 |
| MKKGY Merck KGaA ADR |
-1.13 3.48% | 31.32 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
-5.4 3.30% | 158.31 | 21.73 | 14.95 | 3.16 | 2.15 | 3.56 | 12.82 |
| GALDY GALDERMA GROUP AG |
-0.13 0.32% | 40.45 | 74.21 | 41.67 | 8.64 | 5.55 | 9.15 | 42.22 |
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.
85 Dan Road, Canton, MA, United States, 02021
| Name | Title | Year Born |
|---|---|---|
| Mr. Gary S. Gillheeney Sr. | Pres, CEO & Director | 1955 |
| Mr. David C. Francisco | Chief Financial Officer | 1966 |
| Mr. Patrick Bilbo | Chief Operating Officer | 1962 |
| Ms. Lori H. Freedman B.A., Esq., J.D. | VP & Gen. Counsel | 1967 |
| Mr. Kurt Matheson | VP of Marketing | NA |
| Mr. Thomas L. Pearl | VP of HR | NA |
| Dr. Zorina Pitkin | Sr. VP of Quality Systems | NA |
| Mr. Brian Grow | Chief Commercial Officer | 1976 |
| Mr. William R. Kolb CPA | Sec. | NA |
| Mr. Gary S. Gillheeney Sr. | President, CEO, Chair of the Board | 1955 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...